Encompass Health reiterates FY2023 guidance at investor meeting on May 22

Encompass Health Corp

Reaffirms FY2023 net operating revenue of $4,700M-$4,770M.
Reaffirms FY2023 Adjusted EBITDA of $870M-$910M.
Reaffirms FY2023 Adjusted EPS of $2.94-$3.23.
CEO Mark Tarr and CFO Doug Coltharp to participate in investor meeting in Birmingham, AL on May 22, 2023.
Guidance unchanged from April 27, 2023 earnings release and April 28, 2023 conference call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.